‘Benign' vein issue behind Trump's swollen legs: White House
The presidential physician found Trump, 79, has 'chronic venous insufficiency' — a condition where damaged leg veins fail to keep blood flowing properly — Press Secretary Karoline Leavitt told reporters, calling it a 'benign and common condition.'
Responding to speculation over recent photos showing bruising on Trump's hand, Leavitt said 'this was consistent with minor soft tissue irritation from frequent handshaking and the use of aspirin, which is taken as part of a standard cardiovascular prevention regimen.'
Trump became the oldest person in history to assume the presidency when he began his second term this January, replacing Democrat Joe Biden, who stepped down at 81.
The Republican frequently boasts of his energy levels and the administration recently even posted an image depicting him as Superman.
In April, Trump said after undergoing a routine medical check-up that he was in 'very good shape.'
Leavitt's revelations follow viral online discussions about the president's visibly swollen ankles and discolored right hand.
She said he had undergone 'a comprehensive examination, including diagnostic vascular studies. Bilateral lower extremity venous doppler ultrasounds were performed and revealed chronic venous insufficiency, a benign and common condition, particularly in individuals over the age of 70.'
'Importantly, there was no evidence of deep vein thrombosis or arterial disease,' she said.
All Trump's test results 'were within normal limits,' she said and he had a 'normal cardiac structure and function, no signs of heart failure, renal impairment or systemic illness.'
The hand issue, she said, was linked to the aspirin he takes in a 'standard' cardiovascular health program.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
9 hours ago
- Al Arabiya
Nih cuts spotlight a hidden crisis facing patients with experimental brain implants
Carol Seeger finally escaped her debilitating depression with an experimental treatment that placed electrodes in her brain and a pacemaker-like device in her chest. But when its batteries stopped working, insurance wouldn't pay to fix the problem, and she sank back into a dangerous darkness. She worried for her life, asking herself: 'Why am I putting myself through this?' Seeger's predicament highlights a growing problem for hundreds of people with experimental neural implants, including those for depression, quadriplegia, and other conditions. Although these patients take big risks to advance science, there's no guarantee that their devices will be maintained – particularly after they finish participating in clinical trials – and no mechanism requiring companies or insurers to do so. A research project led by Gabriel Lázaro-Muñoz, a Harvard University scientist, aimed to change that by creating partnerships between players in the burgeoning implant field to overcome barriers to device access and follow-up care. But the cancellation of hundreds of National Institutes of Health grants by the Trump administration this year left the project in limbo, dimming hope for Seeger and others like her who wonder what will happen to their health and progress. An ethical quagmire – Unlike medications, implanted devices often require parts, maintenance, batteries, and surgeries when changes are needed. Insurance typically covers such expenses for federally approved devices considered medically necessary but not experimental ones. A procedure to replace a battery alone can cost more than $15,000 without insurance, Lázaro-Muñoz said. 'While companies stand to profit from research, there's really nothing that helps ensure that device manufacturers have to provide any of these parts or cover any kind of maintenance,' said Lázaro-Muñoz. Some companies also move on to newer versions of devices or abandon the research altogether, which can leave patients in an uncertain place. Medtronic, the company that made the deep brain stimulation or DBS technology Seeger used, said in a statement that every study is different and that the company puts patient safety first when considering care after studies end. 'People consider various possibilities when they join a clinical trial.' The Food and Drug Administration requires the informed consent process to include a description of reasonably foreseeable risks and discomforts to the participant, a spokesperson said. However, the FDA doesn't require trial plans to include procedures for long-term device follow-up and maintenance, although the spokesperson stated that the agency has requested those in the past. While some informed consent forms say devices will be removed at a study's end, Lázaro-Muñoz said removal is ethically problematic when a device is helping a patient. Plus, he said some trial participants told him and his colleagues that they didn't remember everything discussed during the consent process, partly because they were so focused on getting better. Brandy Ellis, a 49-year-old in Boynton Beach, Florida, said she was desperate for healing when she joined a trial testing the same treatment Seeger got, which delivers an electrical current into the brain to treat severe depression. She was willing to sign whatever forms were necessary to get help after nothing else had worked. 'I was facing death,' she said. 'So it was most definitely consent at the barrel of a gun, which is true for a lot of people who are in a terminal condition.' Patients risk losing a treatment of last resort – Ellis and Seeger, 64, both turned to DBS as a last resort after trying many approved medications and treatments. 'I got in the trial fully expecting it not to work because nothing else had. So I was kind of surprised when it did,' said Ellis, whose device was implanted in 2011 at Emory University in Atlanta. 'I am celebrating every single milestone because I'm like: 'This is all bonus life for me.'' She's now on her third battery. She needed surgery to replace two single-use ones, and the one she has now is rechargeable. She's lucky her insurance has covered the procedures, she said, but she worries it may not in the future. 'I can't count on any coverage because there's nothing that says even though I've had this and it works that it has to be covered under my commercial or any other insurance,' said Ellis, who advocates for other former trial participants. Even if companies still make replacement parts for older devices, she added, availability and accessibility are entirely different things given most people can't afford continued care without insurance coverage. Seeger, whose device was implanted in 2012 at Emory, said she went without a working device for around four months when the insurance coverage her wife's job at Emory provided wouldn't pay for battery replacement surgery. Neither would Medicare, which generally only covers DBS for FDA-approved uses. With her research team at Emory advocating for her, Seeger ultimately got financial help from the hospital's indigent care program and paid a few thousand dollars out of pocket. She now has a rechargeable battery, and the device has been working well. But at any point, she said that could change. Federal cuts stall solutions – Lázaro-Muñoz hoped his work would protect people like Seeger and Ellis. 'We should do whatever we can as a society to be able to help them maintain their health,' he said. Lázaro-Muñoz's project received about $987,800 from the National Institute of Mental Health in the 2023 and 2024 fiscal years and was already underway when he was notified of the NIH funding cut in May. He declined to answer questions about it. Ellis said any delay in addressing the thorny issues around experimental brain devices hurts patients. 'Planning at the beginning of a clinical trial about how to continue treatment and maintain devices,' she said, 'would be much better than depending on the kindness of researchers and the whims of insurers.' 'If this turns off, I get sick again. Like, I'm not cured,' she said. 'This is a treatment that absolutely works but only as long as I've got a working device.'
Al Arabiya
2 days ago
- Al Arabiya
Following Venus Williams' comment on health insurance, here's what to know about athlete coverage
Venus Williams' recent singles win at the D.C. Open showcased her longevity and brought attention to health coverage for aging athletes following a joking comment she made in an on-court interview. 'I had to come back for the insurance,' the five-time Wimbledon champion said after Tuesday's match, her first in 16 months. 'They informed me this year that I'm on COBRA, so it's like I got to get my benefits on.' The 45-year-old Williams, who has won seven major singles titles in her career, became the second-oldest woman to win a tour-level singles match in professional tennis with Tuesday's victory. After losing on Thursday, she acknowledged that her comment on health insurance was 'a fun and funny moment.' The Consolidated Omnibus Budget Reconciliation Act, more commonly referred to as COBRA, allows Americans to stay on their employer's insurance plan for a limited amount of time after leaving their job. It comes with high costs. Williams' comment led to questions about health insurance in the sports world. For most active professional athletes, partially or fully subsidized health insurance is provided by their league or governing body and guaranteed in their collective bargaining agreement. A CBA is an agreement reached between a league and its players that guarantees certain levels of player compensation and benefits and can be renegotiated every few years. So, when athletes are playing, they're usually covered. But Williams coming back to the sport after a 16-month hiatus brought to light how long that insurance lasts – or doesn't last – for athletes when they're not playing. Women's Tennis: In the WTA, the governing body of the women's tour, players are eligible to enroll in the health insurance plan if they are ranked in the top 500 in singles or top 175 in doubles and have played a minimum of three WTA 250 level or above tournaments that year. If players are in the top 150 in singles or top 50 in doubles, the WTA will pay a portion of the premiums. If a player is no longer eligible under those requirements, they can enroll in COBRA for up to 18 months, which is likely the situation that Williams was referencing. That is also the WTA's only option for retiring players. 'Nobody wants to be on COBRA, right?' Williams said after her second-round loss on Thursday night. 'That remains an issue in my life … Obviously (the interview was) a fun and funny moment, but it's an issue that people are dealing with, so it is serious.' Men's Tennis: The ATP provides health insurance to men's tennis players who rank in the top 250 in singles or top 50 in doubles. All other players with a ranking point are given the opportunity to purchase health insurance through the ATP's provider. For retired players, the only option is COBRA for up to three years. Golf: As an individual sport without a CBA, golf tours vary. They do have a group insurance plan that is available to active members of the PGA Tour, the PGA Tour Champions (the tour for golfers over 50), and the Korn Ferry Tour (the feeder circuit for the PGA). For players who meet certain performance criteria, including how many tournaments they played and how often they won, the PGA will partially subsidize the plan. In retirement, players are responsible for their own insurance. Some players join the PGA Tour Champions after the PGA Tour and play into their mid-60s, during which they maintain coverage. Top players can receive a subsidy from the PGA in retirement. The LPGA Tour, the women's professional golf tour, started offering its players fully funded health insurance for the first time this year. Before this year, players were given a 4000 stipend. NBA: NBA players have access to one of the most inclusive insurance plans in retirement. If they played at least three years in the league, retired NBA players are eligible for fully-funded health insurance in retirement, and if they played at least 10 years, they will have healthcare covered for their entire family. WNBA: WNBA players are fighting for retirement healthcare as part of their new CBA, which they are currently negotiating with the league. Those negotiations have been heated, and the most recent meeting between the two sides last weekend did not result in an agreement. One unique facet of the W's healthcare is that athletes who have spent more than eight years in the league can be reimbursed up to 20000 a year for costs related to adoption, surrogacy, egg freezing, or additional fertility treatments. NFL: The NFL has less long-term coverage for retirees than most other team sport leagues – athletes who played in the league for at least three years can remain on the NFL health insurance plan but only for five years into retirement. NHL: NHL players who have played more than 160 games with the league, which is about two seasons, are eligible to buy NHL health insurance for their retirement. The retirement insurance plan is eligible for partial subsidization from the league. MLB: Baseball players who spent at least four years in the league have the option to pay premiums to stay on the MLB's healthcare plan indefinitely. Minor League Baseball has its own separate CBA, which also guarantees health insurance for active players. In the minors, however, players who get cut or leave the league lose coverage at the end of that month.
Al Arabiya
3 days ago
- Al Arabiya
UnitedHealth says it is under a federal investigation and cooperating
Shares of UnitedHealth Group dove early Thursday after the health care giant said it was under a Department of Justice investigation. The company said it has started complying with both criminal and civil requests from federal investigators and it was cooperating with them. UnitedHealth has a long record of responsible conduct and effective compliance, the company said in a Securities and Exchange Commission filing. Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. UnitedHealth Group Inc. said in February that it was'nt aware of the start of any new activity as the paper reported. The company said Thursday that it reached out to the Justice Department after reviewing media reports about investigations into certain aspects of the company's participation in the Medicare program. UnitedHealth runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. Company shares have mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. The stock price dropped 3 percent, or 9.63, to 283 shortly before markets opened Thursday.
